Literature DB >> 22422328

Evaluating heparin-induced thrombocytopenia: the old and the new.

Chee Wee Tan1, Christopher Morice Ward, Marie-Christine Morel-Kopp.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a rare but potentially serious complication of heparin use. Prompt diagnosis is crucial and requires the integration of clinical assessment and laboratory testing. Pretest clinical scoring systems (i.e., 4 Ts) have been established. Immunoassays can detect the presence of antibodies directed toward heparin-platelet factor 4 (H-PF4) complexes, but provide no information about their ability to activate platelets. A low clinical score, when combined with a negative immunoassay result obviates the need for further testing. However, immunoassays and 4 Ts scores have only modest specificity. Functional testing (serotonin release assay or heparin-induced platelet activation) remain important in confirming the presence of pathogenic H-PF4 antibodies, but are technically demanding to perform and limited in guiding clinical decisions in the acute setting. This review evaluates current immuno- and functional assays available in the laboratory diagnosis of HIT, and describes recent attempts to improve the specificity of enzyme immunoassays, including adopting an immunoglobulin G-specific assay and raising the optical density value cutoff for a positive result. The importance of donor selection and newer functional assays, including flow cytometry-based assays, are also discussed. A current approach to integrating clinical scoring, immunoassays, and functional testing for HIT is also outlined. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22422328     DOI: 10.1055/s-0032-1301411

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

Review 1.  Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  What's new about heparin-induced thrombocytopenia type II.

Authors:  Yasser Sakr
Journal:  Intensive Care Med       Date:  2015-04-23       Impact factor: 17.440

Review 3.  Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums.

Authors:  Sachin Gupta; Ravindranath Tiruvoipati; Cameron Green; John Botha; Huy Tran
Journal:  World J Crit Care Med       Date:  2015-08-04

4.  Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study.

Authors:  Anika Witten; Juliane Bolbrinker; Andrei Barysenka; Matthias Huber; Frank Rühle; Ulrike Nowak-Göttl; Edeltraut Garbe; Reinhold Kreutz; Monika Stoll
Journal:  J Mol Med (Berl)       Date:  2018-06-22       Impact factor: 4.599

Review 5.  Rare thrombophilic conditions.

Authors:  Gian Luca Salvagno; Chiara Pavan; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2018-09

6.  Thrombocytopenia caused by low-dose heparin supplementation of parenteral nutrition solution.

Authors:  Eunyoung Lee; Jeong-Ok Lee; Yoojoo Lim; Ji-Yeon Kim; Hyun Kyung Kim; Soo-Mee Bang
Journal:  Blood Res       Date:  2013-06-25

Review 7.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

8.  Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia.

Authors:  B D Wines; C W Tan; E Duncan; S McRae; R I Baker; R K Andrews; S Esparon; E E Gardiner; P M Hogarth
Journal:  J Thromb Haemost       Date:  2018-11-20       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.